RE:RE:@PRC - Potential TFC-1067 - year 1-5Once Sirona agrees on a contract, it is out of their hands. They are relying on the company involved to produce various products, and push for sales. Obviously so far R+F has done diddly squat for Sirona. It will take more than one product with R+F to make it worthwhile. Even then the payout to Sirona is minuscule. Upfront payment of new products...then depends on how much TFC-1067 is used in the product, and then the ammount of products sold.
Abbvie should be a different ballgame. A totally run company than R+F, and a totally different contract. I see them pushing their product harder, and having various products with TFC-1067 in them. The thought of having a skin lightner for larger areas and not just mainlly for spots, is key here. There is a huge market for this, as we all know. Now we shall see what Abbvie does with Sirona's product. All these numbers about future sales mean nothing if Abbvie doesn't go all out on taking a decent percentage of the market.